The Risk Does Not End at the Cutoff

What if the biggest mistake in public health is treating prevention and detection as separate jobs?

One policy asks whether a person should receive an annual low dose CT scan. Another asks whether a new tobacco product should be allowed onto the market. They appear to belong to different worlds: one is clinical medicine, the other regulatory administration. Yet both are trying to answer the same difficult question:

How should society act when risk is real, unevenly distributed, and only partly visible?

The answer matters because public health systems often make decisions using convenient categories rather than living patterns of risk. A former smoker who quit 16 years ago may be excluded from screening despite substantial accumulated risk. A new tobacco product may be judged not only by whether it harms its user, but also by whether it attracts nonusers or changes quitting behavior across the population.

These are connected problems. Both reveal the limits of rules that focus on a single moment, a single person, or a single metric. The deeper lesson is that effective public health requires a risk lifecycle: preventing exposure where possible, monitoring changing risk, and intervening before damage becomes irreversible.

The danger of mistaking a cutoff for a boundary

Every public health system needs thresholds. Screening cannot be offered to everyone indefinitely, and regulators cannot evaluate every product using an infinite list of hypothetical outcomes. Thresholds turn uncertainty into action. But they also create a psychological trap: once a person or product falls on one side of a line, we begin to treat the line as if it were a law of nature.

Consider the years since someone stopped smoking. A rule that limits screening to people who quit within the last 15 years sounds precise. Precision, however, is not the same as truth. The biological effects of smoking do not expire on a policy anniversary. Risk may decline after quitting, but age continues to accumulate risk, and prior exposure remains part of a person’s history.

The same problem appears in smoking history. Pack years are useful because they estimate cumulative exposure, but they are still an approximation. Two people with the same number of pack years may have different occupational exposures, genetic susceptibility, air pollution exposure, or patterns of smoking. A threshold can organize a decision, but it cannot fully explain the person standing in front of the clinician.

This is the boundary illusion: the belief that a category boundary marks a sharp change in reality. In practice, risk usually behaves more like a slope than a staircase.

A policy threshold is a tool for allocating attention. It is not a biological border.

This distinction is essential. If a screening rule excludes someone who remains meaningfully vulnerable, the rule has not discovered that the person is safe. It has merely stopped looking. That can be especially consequential when early detection changes the odds of successful treatment.

The problem is not that thresholds exist. The problem is that institutions often forget to update them when evidence reveals who has been left outside them. Groups such as women, Hispanic people, Asian people, and African American people may experience different levels of lung cancer risk at comparable smoking histories. A rule calibrated around the risk profile of white men can appear neutral while producing unequal protection.

In this sense, fairness is not simply a matter of applying the same rule to everyone. It is a matter of asking whether the rule measures risk accurately across populations.

From individual treatment to population feedback

The regulatory logic for tobacco products offers a broader model. A new product is not evaluated solely by asking whether it is harmful to the person who uses it. Regulators must consider the product’s effects on the population as a whole, including current users, nonusers, and people who might begin using tobacco because the product is available.

That requires at least three questions:

1. Will current tobacco users become more likely to quit or less likely to quit?
2. Will people who do not currently use tobacco be attracted to the product?
3. What are the risks and benefits when these effects are combined across the population?

This is a major conceptual shift. It treats a product not as an isolated object, but as an intervention in a social system. The relevant unit of analysis is not just the individual user. It is the flow of people into, through, and out of tobacco use.

Imagine a new product that is less harmful than cigarettes for an adult smoker who switches completely. That fact could matter greatly for that individual. But suppose the product also appeals to teenagers who otherwise would never have used nicotine, or encourages smokers to use both products instead of quitting. The population result may be very different from the result for a single switcher.

This is the portfolio problem of public health. A policy can generate benefits for one group while creating costs for another. Good decisions therefore need to examine the entire portfolio of outcomes rather than celebrate the most favorable individual case.

The same logic applies to screening. A scan can detect a tumor early, but screening also has costs: false positives, anxiety, invasive follow up procedures, radiation exposure, and the diversion of medical resources. The decision is not whether screening is good in the abstract. It is whether screening is beneficial for a population with a particular distribution of risk, access, age, and competing health needs.

Both tobacco regulation and cancer screening are therefore forms of systems medicine. They ask not merely, “Does this help?” but “For whom, under what conditions, and with what downstream effects?”

The hidden connection: prevention and detection are one loop

Prevention is usually imagined as acting before illness, while detection is imagined as acting after risk has already materialized. That distinction is useful, but incomplete. In a functioning health system, prevention and detection should form a continuous feedback loop.

Tobacco regulation operates upstream. It attempts to shape the number of people who start using tobacco, the number who quit, the products they use, and the harms those products create. Screening operates downstream. It looks for disease among people whose risk has already become substantial.

But downstream evidence should influence upstream policy, and upstream policy should influence downstream surveillance.

If screening data show that lung cancers are being diagnosed in people excluded by an old rule, that is not merely a clinical inconvenience. It is feedback about how exposure, aging, quitting, and demographic differences interact. It may indicate that the policy’s model of risk is incomplete.

Likewise, if a newly authorized tobacco product attracts nonusers or reduces quitting, those population effects should influence future regulatory decisions and screening priorities. A product’s consequences do not end when it receives a marketing order. The decision should be treated as a hypothesis that requires observation.

This suggests a simple framework with four stages:

1. Shape exposure

Reduce the number of people who encounter a harmful agent, or reduce the intensity and duration of exposure. Tobacco regulation belongs primarily here, although its effects extend across the entire lifecycle.

2. Measure evolving risk

Track who is exposed, who quits, who relapses, who switches products, and who develops disease. Measurement must include groups that conventional categories may overlook.

3. Detect damage early

Offer screening or monitoring where the expected benefit justifies the costs. Eligibility should reflect current risk, not merely inherited administrative categories.

4. Revise the model

Use outcomes to update thresholds, coverage rules, product assessments, and clinical guidance. A policy that cannot learn is not a prevention system. It is a one time guess.

This fourth stage is often neglected. Institutions publish a rule, communicate it, and then treat implementation as the end of the process. In reality, publication should be the beginning of a measurement cycle.

Why static rules fail in dynamic risk environments

Smoking illustrates why risk management cannot rely on a single variable. A person’s risk changes with age, cumulative exposure, time since quitting, environmental conditions, family history, and access to care. These variables interact. A decline in one source of risk may be offset by an increase in another.

A person who quit smoking long ago may have lower smoking related risk than they had at the moment of quitting. Yet they are also older, and cancer risk generally accumulates with age. The relevant question is not whether quitting helped. It clearly did. The relevant question is whether the remaining risk has fallen below the point at which screening no longer makes sense.

That is a different question from “How long ago did this person quit?” Time since quitting can be part of a risk model, but it should not automatically replace the model.

The same principle applies to tobacco products. A regulator cannot judge a product solely by its toxicology in a laboratory or by its potential benefit to an existing smoker. It must examine behavior over time. Does the product lead to complete switching, dual use, initiation, or cessation? The population response is not a fixed property of the device or substance. It depends on pricing, marketing, flavors, availability, social meaning, and who encounters it.

This is why static eligibility rules and static product judgments are structurally similar. Both compress a changing system into a snapshot.

A better approach is not to eliminate rules, but to add three qualities to them:

First, proportionality. The intensity of intervention should rise with expected risk. People just below a threshold should not be treated as if they are categorically safe.

Second, inclusiveness. Models should be tested for systematic blind spots. If a rule excludes certain populations more often despite comparable or greater risk, the rule needs examination.

Third, reversibility. Decisions should be revisable when new evidence appears. This is especially important for products introduced into populations with unpredictable behavior.

A practical mental model: the risk budget

One useful way to reason about these decisions is to imagine that every public health system has a limited risk budget. It cannot eliminate all risk, fund every scan, or perfectly predict every behavior. The question is how to spend attention where it prevents the most serious and avoidable harm.

Spending the risk budget well means distinguishing between three kinds of uncertainty.

Known risk is danger supported by strong evidence, such as the relationship between substantial smoking exposure and lung cancer. The response should be direct and well resourced.

Hidden risk is danger that existing categories fail to capture, such as people whose cancer risk remains significant after they fall outside a years since quitting rule. Hidden risk calls for better measurement and broader models.

Transferred risk occurs when an intervention reduces harm for one group while shifting it elsewhere. A tobacco product that helps some adults switch but increases initiation among nonusers may transfer risk across the population.

These categories lead to different actions. Known risk calls for prevention and treatment. Hidden risk calls for surveillance and model revision. Transferred risk calls for population level evaluation rather than individual anecdotes.

The framework also clarifies why the most compelling stories can mislead. One former smoker may be diagnosed after losing access to screening, but a single case does not determine the optimal policy. Conversely, one smoker may successfully switch products, but that success does not prove a product benefits public health overall. Individual stories are morally important, yet policy must also examine patterns.

The strongest system uses both levels of evidence: the person in the clinic and the population in the data.

What institutions should do differently

For clinicians, the practical implication is to treat guidelines as structured support, not substitutes for judgment. A patient who falls outside a simple cutoff may still warrant a careful risk discussion, especially when age, exposure, family history, environmental conditions, and access to follow up are considered together. Shared decision making becomes especially important when the evidence is strong enough to identify risk but not precise enough to predict an individual outcome.

For regulators, authorization should be understood as the start of an observational period, not a final declaration of safety or benefit. Population effects should be monitored, including initiation among nonusers, cessation among current users, patterns of dual use, and differences across age and demographic groups.

For health systems and insurers, coverage policies should keep pace with updated evidence. A guideline has little practical value if patients cannot access the recommended screening, or if administrative rules preserve an outdated cutoff after clinical organizations have revised it.

For individuals, the lesson is both reassuring and demanding. Quitting smoking remains one of the most important actions a person can take. But quitting does not mean that all accumulated risk disappears, and it should not be used as a reason to ignore age appropriate medical care. Prevention changes the trajectory of risk. It does not erase history.

Key Takeaways

1. Treat thresholds as decision tools, not biological facts. Falling outside a cutoff does not automatically mean falling outside meaningful risk.

2. Think in lifecycles. Evaluate exposure, behavior, disease detection, and long term outcomes as parts of one connected system.

3. Separate individual benefit from population benefit. A product or intervention can help one group while creating risk for another.

4. Look for hidden and transferred risk. Ask who is excluded by the model and where harm may be shifting rather than disappearing.

5. Demand feedback and revision. Policies should contain mechanisms for monitoring outcomes and updating rules when reality contradicts the original model.

The most important shift is conceptual. Public health is not a collection of isolated gates, each asking whether a person qualifies for a scan or whether a product qualifies for the market. It is a system for managing uncertainty across time.

A cigarette, a cessation aid, a screening scan, and an insurance rule may sit at different points in that system, but they all shape the same chain of events: exposure, behavior, risk, detection, treatment, and survival. The central question is not whether we can draw a perfect line between safe and unsafe. We cannot.

The better question is whether our institutions can notice when the line has failed, protect the people it missed, and learn quickly enough to redraw it. That is the real measure of prevention: not the absence of uncertainty, but the presence of a system capable of responding to it.